Top

Published in:

01-01-2018 | Original Article

Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients

Authors: Mei Jin, Zi-Wen Long, Jing Yang, Xiang Lin

Published in: Pathology & Oncology Research | Issue 1/2018

Abstract

This case-control study aims to investigate the correlations of insulin-like growth factor receptor 1 (IGF-1R) and cyclooxygenase 2 (COX-2) expressions with Ras and BRAF genetic mutations, clinicopathological features and prognosis of colorectal cancer (CRC) patients. A total of 213 CRC patients (case group) and 200 healthy individuals (control group) were selected from our hospital. Ras (K-Ras/N-Ras) and BRAF genetic mutations were detected by direct sequencing. The positive expression rates of IGF-IR and COX-2 in CRC and normal tissues were detected using immunohistochemistry. RT-qPCR and Western blotting were applied to detect the mRNA and protein expressions of IGF-IR and COX-2 in CRC tissues and normal tissues. Total mutation rate of N-Ras, BRAF and K-Ras in case group were 5.2%, 12.2% and 47.4%, respectively. The expressions of IGF-IR and COX-2 were higher in CRC tissues with Ras and BRAF mutations than in those without. CRC tissues with Ras mutation showed higher COX-2 expression than those with BRAF mutation. IGF-IR and COX-2 expressions were correlated to infiltration degree, lymphatic metastasis (in CRC tissues with and without Ras and BRAF mutations), and Dukes stages (only in CRC tissues with Ras and BRAF mutations). CRC patients with negative expressions of IGF-IR and COX-2 had significantly higher accumulative survival rate and longer mean survival duration than those with positive expressions of IGF-IR and COX-2. These findings indicate that IGF-1R and COX-2 expressions may be associated with Ras and BRAF genetic mutations, clinicopathological feature and prognosis of CRC patients.

Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR (2013) Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10(3):93–113PubMed

Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, Bilchik AJ (2013) AJCC cancer staging manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg 217(2):181–190. doi:10.1016/j.jamcollsurg.2013.04.018 CrossRefPubMedPubMedCentral

Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, Group EGW (2010) Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70–v77. doi:10.1093/annonc/mdq168 CrossRefPubMed

Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, Gao Y, Yao A, Wang X, Yu L, Sun B (2013) IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 13:59. doi:10.1186/1471-2407-13-59 CrossRefPubMedPubMedCentral

Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA (2013) Meta-analyses of colorectal cancer risk factors. Cancer Causes Control 24(6):1207–1222. doi:10.1007/s10552-013-0201-5 CrossRefPubMedPubMedCentral

Vanamala J, Reddivari L, Radhakrishnan S, Tarver C (2010) Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p 53 signaling pathways. BMC Cancer 10:238. doi:10.1186/1471-2407-10-238 CrossRefPubMedPubMedCentral

Ding J, Zhang ZM, Xia Y, Liao GQ, Pan Y, Liu S, Zhang Y, Yan ZS (2013) LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer 109(4):994–1003. doi:10.1038/bjc.2013.364 CrossRefPubMedPubMedCentral

Yamamoto T, Oshima T, Yoshihara K, Nishi T, Arai H, Inui K, Kaneko T, Nozawa A, Adachi H, Rino Y, Masuda M, Imada T (2012) Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med 3(5):797–802. doi:10.3892/etm.2012.493 CrossRefPubMedPubMedCentral

Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, Liu J (2012) MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 84(3):320–330. doi:10.1016/j.bcp.2012.04.017 CrossRefPubMed

10.

Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H (2010) IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 160(1):90–101. doi:10.1016/j.jss.2008.08.016 CrossRefPubMed

11.

Wu J, Yu E (2014) Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer Metastasis Rev 33(2–3):607–617. doi:10.1007/s10555-013-9482-0 CrossRefPubMedPubMedCentral

12.

King H, Aleksic T, Haluska P, Macaulay VM (2014) Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 40(9):1096–1105. doi:10.1016/j.ctrv.2014.07.004 CrossRefPubMedPubMedCentral

13.

Cheng J, Fan XM (2013) Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol 19(42):7361–7368. doi:10.3748/wjg.v19.i42.7361 CrossRefPubMedPubMedCentral

14.

Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y, Matsubara H (2011) COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18(10):2946–2951. doi:10.1245/s10434-011-1645-z CrossRefPubMed

15.

Roelofs HM, Te Morsche RH, van Heumen BW, Nagengast FM, Peters WH (2014) Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol 14:1. doi:10.1186/1471-230X-14-1 CrossRefPubMedPubMedCentral

16.

Lehingue Y, Urtizberea JA (1986) Tuberculosis control in Malawi. Time distribution of cessation of treatment and proposals for reorientation of the program. Bull Soc Pathol Exot Filiales 79(2):259–265PubMed

17.

Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim YB, Tai IT (2012) Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia 14(7):624–633CrossRefPubMedPubMedCentral

18.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634. doi:10.1200/JCO.2007.14.7116 CrossRefPubMed

19.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 28(31):4697–4705. doi:10.1200/JCO.2009.27.4860 CrossRefPubMed

20.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706–4713. doi:10.1200/JCO.2009.27.6055 CrossRefPubMed

21.

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-folfox4 treatment and ras mutations in colorectal cancer. N Engl J Med 369(11):1023–1034. doi:10.1056/NEJMoa1305275 CrossRefPubMed

22.

Xing M (2015) Braf mutation and thyroid cancer recurrence. J Clin Oncol 33(22):2482–2483. doi:10.1200/JCO.2015.61.4016 CrossRefPubMed

23.

Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) Kras and braf mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the mrc focus trial. J Clin Oncol 27(35):5931–5937. doi:10.1200/JCO.2009.22.4295 CrossRefPubMed

24.

Mastroleo I (2015) Post-trial obligations in the declaration of Helsinki 2013: classification, reconstruction and interpretation. Dev World Bioeth. doi:10.1111/dewb.12099 PubMed

25.

Sarma DP (1988) Dukes’ classification of rectal cancer. South Med J 81(3):407–408CrossRefPubMed

26.

Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjanen K, El-Faitori O, Latto M, Collan Y, Pyrhonen S (2013) High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res 33(8):3137–3143PubMed

27.

Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM (2015) Irs2 copy number gain, kras and braf mutation status as predictive biomarkers for response to the igf-1r/ir inhibitor bms-754807 in colorectal cancer cell lines. Mol Cancer Ther 14(2):620–630. doi:10.1158/1535-7163.MCT-14-0794-T CrossRefPubMed

28.

Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H (2006) Coexpression of the igf-ir, egfr and her-2 is common in colorectal cancer patients. Int J Oncol 28(2):329–335PubMed

29.

Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM (2012) Braf mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon rectum 55(2):128–133. doi:10.1097/DCR.0b013e31823c08b3

30.

Stoeltzing O, Liu W, Fan F, Wagner C, Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ, Ellis LM (2007) Regulation of cyclooxygenase-2 (cox-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-i receptor (igf-ir) system. Cancer Lett 258(2):291–300. doi:10.1016/j.canlet.2007.09.009 CrossRefPubMedPubMedCentral

31.

Wu CM, Li TM, Hsu SF, Su YC, Kao ST, Fong YC, Tang CH (2011) IGF-I enhances alpha5beta1 integrin expression and cell motility in human chondrosarcoma cells. J Cell Physiol 226(12):3270–3277. doi:10.1002/jcp.22688 CrossRefPubMed

32.

Liu JF, Fong YC, Chang CS, Huang CY, Chen HT, Yang WH, Hsu CJ, Jeng LB, Chen CY, Tang CH (2010) Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 9:43. doi:10.1186/1476-4598-9-43 CrossRefPubMedPubMedCentral

33.

Kim HS, Moon HG, Han W, Yom CK, Kim WH, Kim JH, Noh DY (2012) COX2 overexpression is a prognostic marker for stage III breast cancer. Breast Cancer Res Treat 132(1):51–59. doi:10.1007/s10549-011-1521-3 CrossRefPubMed

34.

Thiel A, Mrena J, Ristimaki A (2011) Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev 30(3–4):387–395. doi:10.1007/s10555-011-9312-1 CrossRefPubMed

35.

Lee Y C YCN and, Hsu T (2013) Abstract 1146: Stk4 downregulation promotes tumor invasion/migration and is associated with poor prognosis in human colon cancer. Cancer Res 73 (8 Supplement): 1146–1146

36.

Zare Mirzaei A, Abdorrazaghi F, Lotfi M, Kazemi Nejad Band Shayanfar N (2015) Prognostic value of lymph node ratio in comparison to lymph node metastases in stage iii colon cancer. Iran J Pathol 10(2):127–135

Title: Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients
Authors: Mei Jin
Zi-Wen Long
Jing Yang
Xiang Lin
Publication date: 01-01-2018
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0195-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases

Exosomes Derived from Irradiated Esophageal Carcinoma-Infiltrating T Cells Promote Metastasis by Inducing the Epithelial–Mesenchymal Transition in Esophageal Cancer Cells

Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?

In Vivo Uptake of Rare Earth Metals by Triple-Negative Breast Cancer Cells

Association of CAA and TATC Insertion/Deletion Genetic Polymorphisms in RTN4 3′-UTR with Hepatocellular Carcinoma Risk

cR and pR: The Residual Tumor Classification Revisited

Keynote webinar | Spotlight on antibody–drug conjugates in cancer